Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden by Abubaker, Khalid et al.
Abubaker et al. Molecular Cancer 2013, 12:24
http://www.molecular-cancer.com/content/12/1/24RESEARCH Open AccessShort-term single treatment of chemotherapy
results in the enrichment of ovarian cancer stem
cell-like cells leading to an increased tumor burden
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Erik W Thompson2,6, Jock K Findlay1,5,7 and Nuzhat Ahmed1,2,5,7*Abstract
Over 80% of women diagnosed with advanced-stage ovarian cancer die as a result of disease recurrence due to
failure of chemotherapy treatment. In this study, using two distinct ovarian cancer cell lines (epithelial OVCA 433
and mesenchymal HEY) we demonstrate enrichment in a population of cells with high expression of CSC markers
at the protein and mRNA levels in response to cisplatin, paclitaxel and the combination of both. We also
demonstrate a significant enhancement in the sphere forming abilities of ovarian cancer cells in response to
chemotherapy drugs. The results of these in vitro findings are supported by in vivo mouse xenograft models in
which intraperitoneal transplantation of cisplatin or paclitaxel-treated residual HEY cells generated significantly
higher tumor burden compared to control untreated cells. Both the treated and untreated cells infiltrated the
organs of the abdominal cavity. In addition, immunohistochemical studies on mouse tumors injected with cisplatin
or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125,
epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with
control untreated cells. These results suggest that a short-term single treatment of chemotherapy leaves residual
cells that are enriched in CSC-like traits, resulting in an increased metastatic potential. The novel findings in this
study are important in understanding the early molecular mechanisms by which chemoresistance and subsequent
relapse may be triggered after the first line of chemotherapy treatment.
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Epithelial ovarian cancer (EOC) is the fifth most com-
mon cancer among women and is the leading cause of
death among gynaecological cancers. Over 80% of
women with EOC are diagnosed at a late-stage with dis-
semination of tumor implants throughout the peritoneal
cavity [1]. The combination of cisplatin and paclitaxel
based chemotherapy was introduced as a first line of
treatment for the clinical management of advanced-stage
ovarian cancer patients nearly 17 years ago [2]. Cisplatin
is a DNA strand cross-linking drug that generates DNA* Correspondence: Nuzhat.Ahmed@thewomens.org.au
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reproduction in any medium, provided the ordamage leading to the activation of cyclin-dependent
kinase inhibitors such as p21 and wee1/mik1, which sub-
sequently arrest cells in either G1 or G2 phase [3]. Re-
sistance to cisplatin has been associated with increased
glutathione and metallothionein levels, decreased drug
uptake, increased DNA repair (due to enhanced expres-
sion of excision repair enzymes) and the tolerance of the
formation of platinum-DNA adducts [4]. The status of
p53 mutation plays a significant role in DNA repair, pro-
liferative arrest and apoptosis and there is a correlation
between cancer cell p53 status and cisplatin sensitivity
[5,6]. Paclitaxel on the other hand, is a mitotic inhibitor
that promotes the formation and stabilization of micro-
tubules leading to a cell cycle block at the metaphase to
anaphase transition [7]. In contrast to cisplatin, the cyto-
toxic effect of paclitaxel is independent of p53 status
[8] and alterations in β-tubulin isotypes have beenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Both cisplatin and paclitaxel through distinct molecular
mechanisms trigger an apoptotic cascade resulting in the
death of the majority of ovarian cancer cells. In spite of
this, approximately 80% of ovarian cancer patients ex-
perience incurable recurrent cancer within 6–20 months
post-chemotherapy [1] as a consequence of the survival
of a very small percentage of chemotherapy resistant re-
sidual tumor cells which facilitate the development of re-
current progressive disease [1]. Concerted research
efforts to tackle the failure of combination chemother-
apy have resulted in no effective salvage strategies for
the last 17 years [9]. Hence, there is an increasing pres-
sure to seek alternative approaches, which has resulted
in the use of combinations of drugs that usually belong
to the platinum or taxane families [9]. These alternative
drug combinations have provided temporary hope to the
patients but have had no clinically effective outcome
[9]. To establish an effective treatment protocol for
advanced-stage ovarian cancer patients a systematic ap-
proach is needed to understand responses of ovarian
cancer cells to platinum and taxane-based drugs, indi-
vidually and in combination. In vivo experiments initially
with each drug treatment will result in insights into the
molecules that facilitate the evasion of chemotherapy-
associated cytotoxicity against each individual drug and
the subsequent re-growth of tumour cells as recurrent
tumor masses. This is particularly important for a large
proportion of chemorefractory ovarian cancer patients
who are resistant to platinum-based drugs and are nor-
mally prescribed taxane-based treatment. On the other
hand, some ovarian cancer patients respond badly to-
wards taxane-based drugs and develop serious side ef-
fects, in which case they are prescribed platinum-based
treatment.
We and others have recently demonstrated an associ-
ation between chemoresistance and the acquisition of epi-
thelial mesenchymal transition (EMT) and CSC-like
phenotypes in cancer [10-12] and found chemoresistant
recurrent ovarian tumors to be enriched in CSCs and stem
cell pathway mediators, suggesting that CSCs may con-
tribute to recurrent disease [13,14]. The first involvement
of stem cells in ovarian cancer was reported in the ascites
of an ovarian cancer patient, derived from a single cell that
could sequentially propagate tumors over several genera-
tions [15]. CSCs have also been isolated from ovarian can-
cer cell lines based on their abilities to differentially efflux
the DNA binding dye Hoechst 33342 [16]. This popula-
tion of cells termed the ‘side population’ (SP) displayed the
classical stem cell property in tumorigenicity assays. More
recently, a population of normal murine OSE [17] have
been identified to have putative stem cell characteristics
indicating that these may be the originators of CSCs in the
ovaries. Few other recent reports have shown the presenceof CSCs in ovarian tumors as well as in patients’ ascites
[18-20]. CSCs in these studies were reported to be resist-
ant to conventional chemotherapy and were able to recap-
itulate in vivo the original tumor suggesting that these
CSCs control self-renewal as well as metastasis and
chemoresistance.
In this study, we demonstrate that a short-term single
exposure of chemotherapy (cisplatin, paclitaxel or both
in combination) treatment induced in surviving ovarian
cancer cells a CSC-like profile which was independent of
the type of chemotherapy and the associated cytotox-
icity. We further demonstrate that chemotherapy surviv-
ing residual cells were able to generate tumors with
greater capacity (tumor burden) than control untreated
cells, and that they retained their inherent CSC-like pro-
file in tumor xenografts. These novel findings emphasize
the need to understand the CSC-like phenotype of ovar-
ian tumors which may arise after the first line of chemo-
therapy treatment and may be crucial in facilitating the
aberrant events leading to recurrent disease.
Methods and materials
Cell lines
The human epithelial ovarian cancer line OVCA 433
was derived from the ascites of an ovarian cancer patient
and generously provided by Dr Robert Bast Jr. (MD
Anderson Cancer Centre, Houston, TX). The cell line was
grown as described previously [11]. The human ovarian
HEY cell line was derived from a peritoneal deposit of a
patient diagnosed with papillary cystadenocarcinoma of
the ovary [21]. The cell line was grown as described previ-
ously [22].
Antibodies and reagents
Monoclonal and polyclonal antibodies against CD44,
CD24, CD117, CD133, were obtained from Millipore
(Melbourne, Australia). Monoclonal antibodies against
excision repair complement complex 1 (ERCC1) and
β-tubulin isotype III were obtained from Sapphire Bio-
sciences and Sigma Aldrich (Melbourne, Australia).
Polyclonal antibody against EpCAM was obtained from
Cell Signalling Technology (Beverly, MA, USA). Antibodies
against cytokeratin 7 (cyt7), Ki67, CA125, E-cadherin,
vimentin, Oct4 and CD117 (c-Kit) used for immuno-
histochemistry were obtained from Ventana (Roche,
Arizona, USA).
Treatment of ovarian cancer cells with cisplatin, paclitaxel
and combination of both
Ovarian cancer cell lines OVCA 433 and HEY were
treated with cisplatin and paclitaxel concentrations at
which 50% growth inhibition was obtained (GI50) for
3–5 days. OVCA 433 cells were treated with cisplatin
(5 μg/ml) for five days, paclitaxel (2 ng/ml) and
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taxel) for three days. HEY cells were treated with cis-
platin (1 μg/ml) five days, paclitaxel (1 ng/ml) and
combination (1 μg/ml of cisplatin and 1 ng/ml of pacli-
taxel) for three days. For combination treatment, sam-
ples were screened for response to different combination
of drug treatments and the concentration of combin-
ation treatment which gave the GI50 value while
maintaining the enhancement in resistant phenotype
(ERCC1 and β-tubulin expression) and cancer stem cell
marker expression was chosen for experiments.
Immunofluorescence analysis
Immunofluorescence analysis of ERCC1 and β-tubulin
isotype III was performed as described previously [13].
Images were captured by the photo multiplier tube
(PMT) using the Leica TCS SP2 laser, and viewed on a
HP workstation using the Leica microsystems TCS SP2
software. The mean fluorescence intensity was quantified
using Cell-R software (Olympus Soft Imaging Solutions).
Flow cytometric analysis
Flow cytometry was performed as described previously
[23]. Briefly, untreated or chemotherapy treated cells
were collected and rinsed twice with phosphate buffered
saline (PBS). 106 cells were incubated with primary anti-
body for 1 hr at 4°C and excess unbound antibody was
removed by washing twice with PBS. Cells were stained
with secondary antibody conjugated with phycoerythrin
for 20 minutes at 4°C, washed twice with PBS and then
resuspended in 0.5 ml PBS prior to FACScan analysis. In
each assay background staining was detected using an
antibody-specific IgG isotype. All data were analysed
using Cell Quest software (Becton-Dickinson, Bedford,
MA, USA). Results are presented as histogram overlay.
Sphere forming assay
The sphere forming ability of untreated and chemother-
apy treated OVCA 433 cells and HEY cells were deter-
mined as described previously [11]. The sphere forming
ability of the cells was photographed over 21 days using
a phase contrast microscope (Axiovert 100, Zeiss,
Germany) and assessed with the DeltaPix Viewer soft-
ware (Denmark). Cellular aggregates with a diameter lar-
ger than 50 μm were classified as ‘spheres’.
RNA extraction and Real Time-PCR
RNA extractions were performed using Trizol (Life Tech-
nologies, USA) using the Qiashredder and RNeasy kits
(QIAGEN, Australia) according to the manufacturer’s in-
structions. The concentration and purity of RNA was de-
termined using spectrophotometry (Nanodrop ND-1000
spectrophotometer, Thermo Scientific, USA) and 0.5 μg of
RNA was used for cDNA synthesis. cDNA synthesis wasperformed using Superscript VILO (Invitrogen, Australia)
according to manufacturer’s instructions. Quantitative de-
termination of mRNA levels of various genes was
performed in triplicate using SYBR green (Applied
Biosystems, Australia) as described previously [13]. The
primers for Oct-4A, Nanog, CD44, CD117, EpCAM have
been described previously [11].
Animal studies
Animal ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
the Laboratory Animals of the National Health and
Medical Research Council of Australia. The experimen-
tal protocol was approved by the Ludwig/Department of
Surgery, Royal Melbourne Hospital and University of
Melbourne’s Animal Ethics Committee (Project-006/11),
and was endorsed by the Research and Ethics Commit-
tee of Royal Women’s Hospital Melbourne, Australia.
Animal experiments
Female Balb/c nu/nu mice (age, 6–8 weeks) were
obtained from the Animal Resources Centre, Western
Australia. Animals were housed in a standard pathogen-
free environment with access to food and water.
HEY cells were treated with cisplatin and paclitaxel as
described previously. 5x106 residual cisplatin or pacli-
taxel surviving cells treated for 4 days were injected in-
traperitoneally (ip) in nude mice. Mice were inspected
weekly and tumor progression was monitored based on
overall health and body weight until one of the pre-
determined endpoints was reached. Endpoint criteria in-
cluded loss of body weight exceeding 20% of initial body
weight, anorexia, general patterns of diminished well-
being such as reduced movement and lethargy resulting
from lack of interest in daily activities. Mice were eutha-
nized and organs (liver, stomach, lungs, gastrointestinal
tract, pancreas, uterus, skeletal muscle, colon, kidney,
peritoneum, ovaries and spleen) and solid tumors were
collected for further examination. Metastatic develop-
ment was documented by a Royal Women’s Hospital
pathologist according to histological examination (H &
E staining) of the organs.
Immunohistochemistry of mouse tumors
For immunohistochemistry, formalin fixed, paraffin em-
bedded 4 μm sections of the xenografts were stained
using a Ventana Benchmark Immunostainer (Ventana
Medical Systems, Inc, Arizona, USA). Detection was
performed using Ventana’s Ultra View DAB detection kit
(Roche/Ventana, Arizona, USA) using the method de-
scribed previously [24]. Briefly, tumor sections were
dewaxed with Ventana EZ Prep and endogenous perox-
idase activity was blocked using the Ventana’s Universal
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cadherin, vimentin, CA125, cytokeratin 7 and CD117
(c-Kit) were diluted according to the instruction pro-
vided by the manufacturer. The sections were counter
stained with Ventana Haematoxylin and Blueing Solution.
Immunohistochemistry images were taken using Axioskop
2 microscope, captured using a Nikon DXM1200C
digital camera and processed using NIS-Elements F3.0
software.
Statistical Analysis
Student’s t-test was used for the statistical analyses of
sphere formation and qPCR analysis. Data are presented
as mean ± SEM. A probability level of p < 0.05 was
adopted throughout to determine statistical significance.
Treatment groups were compared with the control
group using one way- ANOVA and Dunnett’s Multiple
Comparison post-tests.
Results
Chemotherapy induced morphological changes in ovarian
cancer cell lines
Treatment with cisplatin resulted in a loss of cell polar-
ity in epithelial OVCA 433 cells and was consistent with
fibroblast-like spindle-shaped morphology in treated
cells as described previously [11,12] (Figure 1A). Due to
the inherent mesenchymal morphology of HEY cells,
changes in mesenchymal morphology in response toFigure 1 Morphological features of OVCA433 and HEY cell lines unde
chemotherapy. (A) OVCA 433 cell line was treated with cisplatin (5 μg/ml
cisplatin and paclitaxel (2.5 μg/ml cisplatin and 1 ng/ml paclitaxel) for three
days, paclitaxel (1 ng/ml) for three days and combination of cisplatin and p
images were assessed by phase contrast microscope. Magnification- 100x,cisplatin treatment was not prominent in HEY cells
(Figure 1B). On the other hand, treatment with paclitaxel
resulted in the appearance of rounded epitheloid cells
within three to five days in both cell lines (Figures 1A-B).
The change to epithelial morphology in response to pacli-
taxel was more prominent in HEY than in OVCA 433
cells, due to their initial mesenchymal appearance. Some
HEY cells seemed to undergo phenomenal cellular en-
largement which was up to five-fold (approximately
50 μm in diameter) more than the control untreated cells.
This may be due to the formation of multi-nucleated cells
in response to paclitaxel treatment which may result from
the inhibition of the mitotic cycle at the metaphase to ana-
phase stage i.e. when the cell fails to divide into two
daughter cells even though the distribution of centro-
some/nucleosome for the daughter cells have occurred.
Morphological changes in response to cisplatin or
paclitaxel were dose-dependent (data not shown). Cis-
platin-induced morphological changes were evident at
concentrations between 1–10 μg/ml (GI50 ~ 5 μg/ml)
for OVCA 433 cells. However, HEY cells responded to
much lower cisplatin concentration of 0.5-5 μg/ml
(GI50 ~ 1 μg/ml) (Figures 1A-B). On the other hand,
paclitaxel-induced epithelial morphology was evident at
a concentration of 0.5-2.5 ng/ml (GI50 ~ 2 ng/ml) for
OVCA 433 cells, and 0.1-2 ng/ml (GI50 ~ 1 ng/ml) for
HEY cells. Similar change to epithelial morphology in
clones of surviving cells, but to a greater extent than thatr normal culture conditions (control) and after treatment with
) for five days, paclitaxel (2 ng/ml) for three days and combination of
days. (B) HEY cell line was treated with cisplatin (1 μg/ml) for five
aclitaxel ( 1 μg/ml cisplatin and 1 ng/ml paclitaxel) for three days. The
scale bar = 10 μm.
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ation treatment (cisplatin + paclitaxel). Both OVCA 433
and HEY demonstrated discrete epithelial colonies and
very few mesenchymal cells which were scattered in be-
tween epithelial cells (Figures 1A-B). Different concentra-
tions of combination treatments were tried but as
described previously [11] the drugs concentration at or
below the GI50 value were used for further study.
Chemotherapy induces the expression of cisplatin and
paclitaxel resistant phenotypes
In order to determine if the morphological changes in-
duced by cisplatin and paclitaxel were consistent with the
chemoresistant phenotype of the ovarian tumors as de-
scribed previously [25,26], we evaluated the expression of
ERCC1 and β-tubulin isotype III by cancer cells which sur-
vived cisplatin, paclitaxel and combination treatments using
immunofluorescence. Compared to untreated control cells,
enhanced expression of ERCC1 was evident in cisplatin,
paclitaxel and combination treated HEY cells (Figure 2).Figure 2 Expression and immunolocalization of (A) ERCC1 and (B) β-t
paclitaxel and combination treatment. The images were evaluated using
described in the Materials and methods section. Cellular staining was visua
fluorescent labelled antibodies. Nuclear staining was visualized using DAPI
experiments. Magnification 200x; scale bar = 10 μM. (C) The mean fluoresc
Imaging Solutions). Significant variations between the groups are indicatedEnhanced β-tubulin isotype III staining was also evident in
HEY cells surviving cisplatin, paclitaxel and combination
treatment (Figures 2A). In most of the cases, the same
population of residual cells stained for ERCC1 and
β-tubulin isotype III after the 3 treatments, suggesting cross
resistance for cisplatin and paclitaxel in HEY cells. How-
ever, β-tubulin isotype III was more dominant in paclitaxel
and combination treated cells (Figure 2B). The expression
of ERCC1 was confined mainly to peripheral membranes
in most cells and few cells displayed nuclear staining. In re-
sponse to paclitaxel treatment an increase in the expression
of β-tubulin isotype III was evident on the peripheral mem-
brane as well as in the nucleus of the surviving cells
(Figure 2B). However, there was more nuclear β-tubulin
isotype III staining compared to membrane staining after
combination treatment (Figure 2B). OVCA 433 cells dem-
onstrated a similar ERCC1 and β-tubulin isotype III stain-
ing pattern (Additional file 1: Figure S1). Quantitative
measurement of the expression of ERCC1 demonstrated
significant enhancement in the expression of ERCC1 inubulin isotype III in HEY cell line in response to cisplatin,
mouse monoclonal (green) and rabbit polyclonal (red) antibodies as
lized using secondary Alexa 488 (green) and Alexa 590 (red)
(blue) staining. Images are representative of three independent
ence intensity was quantified using Cell-R software (Olympus Soft
by ** P < 0.01, *** P < 0.001.
Abubaker et al. Molecular Cancer 2013, 12:24 Page 6 of 15
http://www.molecular-cancer.com/content/12/1/24both HEY and OVCA 433 cells in response to cisplatin
treatment (Figure 2 and Additional file 1: Figure S1). The
expression of ERCC1 was significantly higher in paclitaxel
and combination treated OVCA 433 cells but was not evi-
dent in HEY cells under similar treatment conditions
(Figure 2 and Additional file 1: Figure S1). On the other
hand, β-tubulin isotype III expression was significantly
higher in paclitaxel treated OVCA 433 and HEY cells. No
change in β-tubulin isotype III expression was observed in
cisplatin and combination treated OVCA 433 cells, while
significant enhancement in the expression was observed in
cisplatin and combination treated HEY cells compared to
control untreated cells (Figure 2 and Additional file 1:
Figure S1).
Chemotherapy enhances the expression of CSC markers
Recently a CSC-like phenotype has been demonstrated in
drug resistant ovarian cancer cell lines [16,27] and also in
primary and metastatic ovarian cancer cells from patients
[14,19,28]. In order to assess the status of this phenomenon
in response to cisplatin or paclitaxel and combination
chemotherapy treatments, we assessed the cell surface ex-
pression of some known CSC markers [18] by flowFigure 3 The effects of cisplatin, paclitaxel and combination treatmen
or chemotherapy treated cells were incubated with either control IgG or re
followed by secondary goat anti-mouse IgG conjugated with phycoerythrin
protein expression in control cells while broken lines demonstrate protein
independent experiments.cytometry in OVCA 433 and HEY cells. Moderate to low
expression of CD44, CD24, CD117, CD133 and EpCAM
was evident by flow cytometry in OVCA 433 and HEY cells
(Figure 3 and Additional file 2: Figure S2). The expression
of CD24, CD117, CD133 and EpCAM increased in HEY
cells with cisplatin, paclitaxel and combination treatments,
while there was no change in the expression of CD44 in re-
sponse to cisplatin and combination treatments (Figure 3).
Paclitaxel treatment on the other hand, resulted in the de-
crease of CD44 expression in HEY cells. In OVCA 433 cells
there was an increase in the expression of CD44, CD24,
CD117, CD133 and EpCAM in response to cisplatin, pacli-
taxel and combination treatments (Additional file 2: Figure
S2). However, the increase in CD44 was not pronounced in
response to cisplatin.
The CSC-like profile of drug-treated ovarian cancer
cells was further assessed at the mRNA level by qPCR
(Figure 4). Significantly enhanced mRNA expression of
CD44, EpCAM, CD117, Oct-4 and Nanog in response to
paclitaxel and combination chemotherapy was observed
in HEY cells (Figure 4). Although significant increases in
the mRNA levels of CD44, CD117, Oct4 and Nanog
were observed in response to cisplatin treatment, nots on the expression of CSC-like markers in HEY cells. Untreated
levant primary antibodies against the respective CSC-like markers
. The filled histogram in each figure is control IgG, black lines indicate
expression in treated cells. Results are representative of 3–4
Figure 4 mRNA expression of EpCAM, Nanog, CD44, CD117 and Oct4 in HEY cell line in response to chemotherapy treatments
(cisplatin, paclitaxel and combination). Cells were treated with or without chemotherapy, RNA was extracted, cDNA was prepared and qPCR was
performed as described in the Materials and methods section. The resultant mRNA levels were normalized to 18S mRNA. The experiments were
performed using four independent HEY samples in triplicate. Significant intergroup variations are indicated by *P <0.05, ** P < 0.01, *** P < 0.001.
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served. Hence, the results obtained for EpCAM and
CD44 in response to cisplatin treatment differed at the
protein and mRNA levels (Figure 4). In OVCA 433 cells
however, the mRNA expression of CD44, EPCAM,
CD117, Oct4A and Nanog was significantly enhanced
under all three treatment conditions compared to un-
treated controls (Additional file 3: Figure S3).
As sphere formation has been described as an important
feature for the survival of ovarian CSCs [15], we evaluated
the sphere forming abilities of control, cisplatin, paclitaxel
and combination treated HEY and OVC 433 cells (Figure 5
and Additional file 4: Figure S4). In long term cultures,control and chemotherapy treated cells demonstrated the
ability to form spheres on low attachment plates (Figure 5
and Additional file 4: Figure S4). Within 21 days, the ag-
gregates formed by cisplatin, paclitaxel and combination
therapy treated cells took the shape of spheres with a de-
fined outer rim and were significantly greater in numbers
than control cells (Figure 5 and Additional file 4: Figure
S4). However, majority of the spheres formed by
paclitaxel-treated HEY cells were much bigger in size than
the spheres generated from cisplatin or combination
treated cells. This was due to the aggregation of relatively
bigger multinucleated cells. Hence, the number of spheres
with a diameter larger than 50 μm was less than the
Figure 5 Effects of chemotherapy on the sphere forming ability of HEY cells. (A) The sphere-forming assay was performed on low
attachment plates as described in the Material and methods section. The total number of spheres was counted in the 24 well plates after 21 days
as described in the Methods and materials. The experiment was performed three times in triplicate. Images are representative of a section of a
24 well plate. Black arrows indicate disaggregating cells in control spheres in 21 days. Magnification 200x; scale bar = 10 µM. (B) Significantly
different from control untreated cells indicated by *P<0.05, *** P<0.001.
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each field counted under the microscope (Figure 5). In re-
sponse to combination treatment, cells produce viable
spheres but these were smaller than spheres formed by ei-
ther cisplatin or paclitaxel treated cells. This may be due
to the mixture of epithelial and mesenchymal cells which
may not have the inherent capacity to aggregate and form
bigger spheres. Many cellular aggregates (spheres) formed
from control untreated cells disaggregated within the
21 day time point but those formed by drug-treated cells
persisted, suggesting that chemotherapy transformed re-
sidual cells have a greater ability to survive in anchorage
independent conditions and are enriched in self-renewing
capability compared to control untreated cells.
Residual cancer cells after chemotherapy treatments
exhibited metastatic and CSC-like features in nude mice
In order to assess if the residual cancer cells after
chemotherapy treatment retain tumorigenic abilities, an
in vivo mouse intra-peritoneal (ip) HEY xenograft model
was established. Five out of six mice injected with un-
treated HEY cells developed solid tumors in the form of
3–4 small lesions (<0.5 cm3) in the peritoneum within
six to eight weeks. Tumors weighing 4.7% ± 1.1 of the total
body weight were observed in all five cases (Figure 6). All
twelve mice injected with the same number (5×106) of cis-
platin or paclitaxel treated cells (n = 6 in each group)developed tumors at the same time as control untreated
cells, but with significantly enhanced tumor burden, being
almost double that seen for cisplatin treated (8.7% ± 2.1 of
the total body weight) and three-fold that of paclitaxel
treated cells (13.32% ± 2.3 of the total body weight)
(Figure 6). H & E staining of tumor infiltrated organs gen-
erated by control and treated cells showed the epithelial
morphology of the cells infiltrating the abdominal organs
(Figure 7). Injected control cells in mouse infiltrated liver,
pancreas, stomach and colon but surrounded the kidney
with no invasion (Figure 7A-B). Invasion into the liver and
pancreas was common for cisplatin and paclitaxel treated
injected cells (Figure 7A). Paclitaxel-treated HEY cells in-
vaded kidney, but the invasion with the cisplatin treated
cells was not consistent and differed between mice. In two
out of the three mice analysed invasion to the kidney was
observed, but in one mouse, cells surrounded the kidney
with no invasion (Figure 7B).
Immunohistochemistry analysis of mouse tumors
demonstrated positive staining of cyt 7 in xenografts
from both untreated and treated HEY cells (Figure 8A).
Mouse xenografts also exhibited positive staining for
Ki67, which was enhanced in cisplatin and paclitaxel
treated cell-derived xenografts compared to untreated
control xenografts (Figure 8A). Patches of E-cadherin
staining localized to discrete cell-cell junctions were ob-
served in untreated HEY xenografts (Figure 8B). This
Figure 6 Tumor burden of mice injected with untreated control and chemotherapy treated HEY cells. (A) Total tumor burden obtained
from mice 6 weeks after ip injection of control and chemotherapy treated HEY cells. 5x106 cells were inoculated in each case. (B) Average
percentage of tumor debulked from mice 6 weeks post ip injection of control and chemotherapy treated HEY cells. The average tumor weight
was standardised to total mouse body weight. Data has been extrapolated from a minimum of n = 6 mice in each group. Significant increase in
tumor burden in cisplatin and paclitaxel treated HEY cell derived tumors compared to control untreated group, *P < 0.05. Images represent
tumors debulked from one mouse in each group.
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taxel treated cell derived mouse xenografts (Figure 8B).
A similar pattern of enhanced staining of CA125 was
evident in treated cell mouse xenografts, compared to
xenografts obtained from mice injected with untreated
cells (Figure 8A). Mouse xenografts were also assessed
for the expression of stem cells marker CD117 (c-Kit)
and the embryonic stem cell marker Oct4. A dramatic
increase in the expression of these two markers was ob-
served in xenografts derived from cisplatin or paclitaxel
treated cells, compared to the xenografts derived from
control cells (Figure 8B).
Discussion
Chemoresistance is a major obstacle towards the suc-
cessful treatment of ovarian cancer patients. The mo-
lecular and the cellular mechanisms of the resistance of
ovarian cancer cells to platinum and taxane-based ther-
apies, the two agents used as standard treatment, re-
mains unknown in vitro and in vivo. In this study we
have used two very different ovarian cancer cell lines,
OVCA 433 (mainly epithelial) and HEY (mainly mesen-
chymal), treated short-term with cisplatin or paclitaxel
or the combination of both to dissect those initial cellu-
lar responses that facilitate the survival of residual cells
and their subsequent regrowth in an in vivo mousemodel. We have demonstrated that cisplatin or pacli-
taxel or combination treatment of ovarian cancer cell
lines, generates in each case a population of residual
cells with features of CSC-like cells. An enhanced ex-
pression of CSC markers in the residual cancer cells
after chemotherapy treatments coincided with an en-
hanced expression of ERCC1 and/or β-tubulin isotype
III, the two proteins commonly associated with resist-
ance of cancer cells to platinum and taxane-based che-
motherapies [29,30]. Enhancement in ERCC1 expression
in response to cisplatin was consistent with the en-
hanced expression of β-tubulin isotype III within the
same population of cells after paclitaxel treatment. How-
ever, in response to paclitaxel and combination treat-
ments a greater degree of β-tubulin isotype III
expression was observed, suggesting that cisplatin resist-
ant cells may be cross resistant to paclitaxel but the re-
verse may not be the case. ERCC1 has been associated
with cisplatin resistance in ovarian tumors and cancer
cell lines [25,29]. Recent clinical trials suggest that pa-
tients with low ERCC1 levels benefit preferentially from
cisplatin-based chemotherapy compared to patients who
have a higher expression of ERCC1 in their tumors [31].
On the other hand, tumors resistant to paclitaxel or can-
cer cell lines rendered resistant to paclitaxel have sub-
stantially enhanced levels of isotypes III or IV β-tubulin
Figure 7 H and E staining of control and chemotherapy treated HEY cell derived tumor associated infiltrated organs in mice. 5 x 106
cells were injected ip in each mouse. (A) Histological images of liver and pancreas showing infiltration of control and chemotherapy treated HEY
cells in mice. (B) Histological images of mice kidney and colon injected with control and chemotherapy treated cells. Control cells surround the
kidney with no invasion. Cisplatin treated cells do not invade kidney. Arrows indicate tumor cells invading the respective organs. Magnification
200X, scale bar = 10 μm.
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specific taxane-resistant tubulin has also been described
in the tumors of ovarian cancer patients [26]. Paired
samples from advanced-stage ovarian cancer patients
who developed clinical paclitaxel resistance showed in-
creases in β-tubulin isotypes I (3.6-fold), III (4.4-fold)
and IV (7.6-fold) [26].Long-term repeated chemo-treatment approaches have
been shown to generate chemoresistant cancer cell lines
with features of CSCs [35,36]. The novelty of the current
study is the demonstration of CSC-like features in ovar-
ian cancer cell lines by a single short-term exposure of
chemotherapeutic agents. The fact that short-term single
exposure of chemotherapeutic agents is capable of
Figure 8 (A-B) Immunohistochemistry images of mouse tumors generated from ip transplantation of control, cisplatin and paclitaxel-
treated HEY cells. Tumor sections were stained with antibodies specific for cyt7, Ki67, CA125, E-cadherin, CD117 and Oct4 as described in the
Methods and material section. Magnification 200X, scale bar = 10 μm. Black arrows indicate specific antigen expression in respective tumor sections.
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genes (ERCC1 and β-tubulin III) and potential CSC
genes, suggests that selection of existing chemoresistant
CSC-like subpopulation of ovarian cancer cells is em-
bedded within the bulk of the original cancer population.
As shown in our previous studies, this pattern of selec-
tion of CSC-like cells is not limited to ovarian cancer
cell lines but can be displayed in tumor cells isolated from
primary ovarian tumors and ascites of ovarian cancer pa-
tients [11]. This suggests that in the clinical scenario, CSC
enriched residual cells are generated in the host tumor
microenvironment after the first round of chemotherapy
treatment. Whether these cells further enrich their CSC-
like characteristics after consecutive chemotherapy treat-
ments or retain the original CSC-like features to facilitate
the re-growth of secondary tumors is not known. How-
ever, we have previously demonstrated that the expression
level of CSC-like markers in OVCA 433 cells remains un-
changed after single or long-term treatments with cisplatin
[12]. In this context, few previous studies have demon-
strated the existence of CSC-enriched side population of
cells [28,37] or CD44, CD117, CD133, CD24 enriched
population of cells in ovarian cancer cell lines or ovarian
cancer patient’s samples [38-40]. These CSC-enriched cells
have been shown to develop tumors on sequential inocu-
lation in nude mice and retain the original CSC-like
phenotype observed in the parental sample.
Recent data suggest that CSCs rely on the presence of
a ‘CSC niche’ which controls their self-renewal and dif-
ferentiation [41]. Current studies have also shown that
residual cells after chemotherapy treatment secrete sol-
uble factors that provide a favourable microenvironment
to facilitate the growth of residual cells [42,43]. This
close relationship between chemotherapy-surviving cells
and their secretory microenvironment represents a po-
tential ‘CSC niche’ that can provide survival signals to
residual cells for re-growth into a recurrent cancer.
Moreover, CSCs can also be generated by the complex
tumor microenvironment composed of diverse stromal
cells, including tissue specific fibroblasts, cancer associ-
ated fibroblasts, tissue specific and bone marrow-derived
mesenchymal stem cells, infiltrating immune cells, endo-
thelial cells and their associated vascular network,
soluble and other growth factors and/or extracellular
matrix component [41]. Growth of recurrent tumors
seems to rely on the permissive microenvironment pro-
vided by each component of ‘CSC niche’. The CSCs re-
tain their exclusive abilities to self-renew and give rise to
differentiated progenitor cells, while staying in an undif-
ferentiated state themselves [41].
In the current study we have demonstrated that both
the epithelial OVCA 433 and mesenchymal HEY cell
lines respond to cisplatin or paclitaxel by enhancing the
expression of CD24, CD117, CD133 and EpCAM.However, the enhancement of CD44 in response to cis-
platin or paclitaxel treatments differed between the cell
lines and may depend on the inherent epithelial or mes-
enchymal phenotype of the cell line. CD44 is not only a
stem cell marker but has been shown to be highly
expressed in cells with mesenchymal phenotype. The
HEY cell line is inherently mesenchymal, with high en-
dogenous expression of CD44 prior to chemotherapy.
On the other hand, OVCA 433 is an epithelial cell line
with a minimal expression of CD44. The addition of cis-
platin drives both the cell lines to a mesenchymal state
[12]. This correlates nicely with a slight increase in the
expression of CD44 in both OVCA 433 and HEY cell
lines. On the contrary, paclitaxel treatment induced a
more epithelial-like morphology in the inherently mes-
enchymal HEY cell line, which may result in the down
regulation of CD44 expression. This holds true only at
the protein level. At the mRNA level, the expression of
CD44 was elevated with all chemotherapy treatments in
both the cell lines. This suggests, an inability of transla-
tion of CD44 mRNA in HEY cells. This may occur due
to epigenetic changes in CD44 with paclitaxel treatment
in HEY cells [44]. However, the disparity of EpCAM ex-
pression at the protein and mRNA levels in HEY cells is
difficult to explain. One possible explanation can be that
DNA damage response initiated by cisplatin has no ef-
fect on the transcriptional expression of EpCAM but it
may trigger enhanced translation of EpCAM from the
existing endogenous EpCAM mRNA.
Tumors generated from control untreated and cis-
platin/paclitaxel treated cells were invasive and invaded
peritoneal organs such as pancreas and liver. With the
small number of tumor xenografts analysed in this study
(n = 3) we have demonstrated some differences in the in-
vasion to kidney by chemotherapy treated cells. No pat-
tern of kidney invasion was observed with control
untreated mice. However, paclitaxel-treated HEY cells
invaded kidney, but the invasion with cisplatin treated
cells was not consistent and differed between mice. In
two out of the three mice analysed, invasion to kidney
was observed, but in one mouse tumor cells surrounded
the kidney with no apparent invasion. This variation in
the invasion pattern between the control and chemo-
therapy treated cells may be due to the phenotypic
changes induced in the cells by the chemotherapeutic
agents or it may be due to the induced ‘CSC-niche’ cre-
ated by the cells within the tumor microenvironment.
Enhanced CSC-like characteristics observed in ovarian
cancer cells after a single dose of chemotherapy treat-
ment were retained in in vivo mouse xenografts
(enhanced expression of Oct4 and CD117 in tumors de-
rived from cisplatin and paclitaxel treated cells). Tumor
cells within the xenografts of chemotherapy treated cells
had a greater proliferative potential as evaluated by
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within the same time frame as that of the tumors de-
rived from control untreated cells. In addition, tumors
derived from chemotherapy treated cells had an en-
hanced expression of CA125 and were more epithelial in
phenotype with enhanced E-cadherin expression com-
pared to tumors generated from control untreated HEY
cells. The relative high abundance of epithelial markers
(enhanced expression of E-cadherin and CA125) in tu-
mors derived from HEY cells treated with chemotherapy
in vitro, compared to untreated control cells, is consist-
ent with our recent observation of ascites tumor cells of
recurrent patients which had an enhanced expression of
epithelial and CSC-like markers compared to tumor cells
of ascites obtained from chemonaive untreated patients
[13]. We have previously reported that ovarian cancer
cells possess a certain level of epithelial mesenchymal
plasticity that allows them to change their phenotype
and acquire different functions and properties under the
influence of the local tumor environment [12,45,46].
Considering that HEY cells have inherent mesenchymal
phenotype and very low/no expression of E-cadherin
and CA125 in vitro, the expression of E-cadherin and
CA125 in vivo control mouse xenografts implies such
plasticity. The dynamics of ovarian tumor cell plasticityFigure 9 Mouse model of chemoresistance and associated recurrence
treatment with cisplatin or paclitaxel in vitro were injected (ip) into nude m
paclitaxel treated cells enriched in CSC-like markers generated significantly
expression of CD117, Oct4, CA125, Ki67 and E-cadherin compared to tumo
chemotherapy treatment promotes CSC-dependent enhanced tumor progin relation to tumor cell dissemination and engraftment
on secondary site is not well understood but the poten-
tial ‘mesenchymal to epithelial transition’ (MET) is as-
sumed to occur in the late phase of ovarian tumor
dissemination when the tumor cells adapt to the
ascites microenvironment [46-49]. The expression of
E-cadherin and CA125 in xenografts obtained from mes-
enchymal HEY cells, and enhancement of that expres-
sion in mouse xenografts derived from residual
chemotherapy treated cells, further illustrates plasticity
related changes in HEY cells influenced by the in vivo
microenvironment which acts as a ‘CSC niche’, and may
facilitate the rapid proliferation of chemotherapy-treated
CSC-rich residual cells resulting in increased tumor bur-
den. These novel observations are consistent with a re-
cent study that demonstrated the epithelial phenotype of
side population cells sorted from ovarian cancer lines
and ascites of ovarian cancer patients [50]. These stem-
like side population cells exhibited decreased adhesive
and invasive potential compared to the more differentiated
non-side population cells and were localized on tumor
boundary when implanted into nude mice along with
non-side population cells [50]. These results suggest that
the relationship between malignant potential, CSC pheno-
type and cellular plasticity in ovarian cancer is ain ovarian cancer. Control untreated and residual HEY cells after
ice (n = 18, n = 6/group) and followed for 5–7 weeks. Cisplatin and
increased tumor burden as well as xenografts with enhanced
rs derived from non treated HEY cells. This suggests that
ression in a mouse model of ovarian cancer.
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stand the processes. In this context, the identification of
E-cadherin rich metastatic tumors in breast and brain can-
cers [48,51,52], and an association between increased
pluripotency and the epithelial subcomponent of human
bladder and prostatic carcinoma cells [53], and normal
breast cells [54] exerts a strong link between epithelial
plasticity and CSCs. Perhaps consistent with this is the ob-
servation that BRCA1-associated basal breast cancers bet-
ter resemble aberrant luminal progenitor cells rather than
the mesenchymal-like mammary stem cells [55,56].
The results from this novel study show that (a) a short-
term early phase chemotherapy treatment leaves residual
cells that are enriched for CSC-like traits, (b) in an in vivo
environment, these cells are more proliferative and result
in a larger tumor burden, and (c) the cells retain the CSC
enriched phenotype in the resultant tumors. These find-
ings are strikingly similar to ovarian cancer patients who
relapse post-chemotherapy treatment with increased
tumor burden and metastasis with recurrent tumors that
are enriched for CSC-like traits [13,14]. On the basis of
our novel findings a model of chemoresistance and recur-
rence in ovarian carcinomas is described in Figure 9.
Additional files
Additional file 1: Figure S1. Expression of chemoresistant phenotype
in OVCA 433 cell line. Expression and immunolocalization of (A) ERCC1
and (B) β-tubulin isotype III in OVCA 433 cell line in response to cisplatin,
paclitaxel and combination treatment. The images were evaluated as
described in Figure 2.
Additional file 2: Figure S2. The effects of cisplatin, paclitaxel and
combination treatments on the expression of CSC-like markers in OVCA
433 cells. The experiment was performed as described in Figure 3.
Additional file 3: Figure S3. mRNA expression of EpCAM, Nanog,
CD44, CD117 and Oct4 in OVCA 433 cell line in response to
chemotherapy treatments (cisplatin, paclitaxel and combination). The
experiment was performed as described in Figure 4.
Additional file 4: Figure S4. Effects of chemotherapy on the sphere
forming ability of OVCA 433 cells. The sphere-forming assay was
performed on low attachment plates as described in figure 5.
Significantly different in the chemotherapy treated cells compared to
control untreated cells. *P<0.05, ** P<0.01.
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